Brief: Nabriva's Xenleta Demonstrates High Efficacy In Patients With Community-Acquired Bacterial Pneumonia

Nabriva Therapeutics

13/10/2020 12:14

Oct 13 (Reuters) - Nabriva Therapeutics PLC  NBRV.O :
    * NABRIVA’S XENLETA DEMONSTRATES HIGH EFFICACY IN PATIENTS
OF
ADVANCED AGE WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP)
    * NABRIVA THERAPEUTICS PLC - ADVERSE EVENT PROFILE AND STUDY
DRUG
DISCONTINUATION RATES WERE SIMILAR ACROSS ALL AGE GROUPS FOR
XENLETA
    * NABRIVA THERAPEUTICS - POOLED ANALYSIS OF DATA BY AGE
GROUP FROM
PIVOTAL LEAP 1 & LEAP 2 PHASE 3 TRIALS TO BE PRESENTED AT CHEST
ANNUAL MEETING 2020
    * NABRIVA THERAPEUTICS - IN LEAP 1 & LEAP 2 TRIALS BY AGE,
XENLETA
SHOWED SIMILAR SAFETY & TOLERABILITY PROFILES ACROSS ALL PATIENT
GROUPS

Source text for Eikon:  ID:nGNX6dgRPj 
Further company coverage:  NBRV.O 

 ((Reuters.Briefs@thomsonreuters.com;))